Trial
NCT01607346
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Epilepsy
Intervention
ezogabine/retigabine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-04